MMS, IFA, and MMS+IFA Supplementation in Pregnant Women: A Randomized Controlled Trial. (NCT07665957) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
MMS, IFA, and MMS+IFA Supplementation in Pregnant Women: A Randomized Controlled Trial.
402 participantsStarted 2026-06-25
Plain-language summary
This study aims to compare the effectiveness of Multiple Micronutrient Supplementation (MMS), Iron-Folic Acid (IFA) supplementation, and combined MMS+IFA supplementation among pregnant women. Maternal anemia and micronutrient deficiencies are common during pregnancy and can adversely affect both maternal and neonatal health outcomes.
A total of 402 pregnant women with gestational age of 20 weeks or less will be randomly assigned to receive MMS, IFA, or combined MMS+IFA supplementation. Participants will be followed throughout pregnancy until delivery. Maternal hemoglobin levels, maternal compliance with supplementation, and neonatal outcomes including birth weight, preterm birth, APGAR scores, and congenital anomalies will be assessed.
The findings of this study will provide evidence to guide antenatal nutrition policies and practices in Pakistan.
Who can participate
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Pregnant women aged 18 years or older Gestational age ≤20 weeks at enrollment Singleton pregnancy Hemoglobin concentration ≥10 g/dL at baseline Willing and able to provide informed consent Willing to comply with study procedures and follow-up visits
Exclusion Criteria:
Severe anemia requiring injectable treatment (hemoglobin \<7 g/dL) Pre-existing diabetes mellitus Pre-existing hypertension Renal disease Current therapeutic iron or micronutrient supplementation beyond routine antenatal supplementation Known fetal congenital anomalies Any medical condition that, in the opinion of the investigator, would interfere with study participation or outcome assessment
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Maternal Hemoglobin Concentration
Timeframe: Baseline, 28 weeks gestation, and 36-37 weeks gestation or at delivery
Trial details
NCT IDNCT07665957
SponsorSindh Institute of Child Health and Neonatology